TRIANA Initiates Dosing of ALK Degrader TRI-611 in Phase 1/2 Trial
Clinical Entry and Development Status
Non-listed company TRIANA Biomedicines completed the first dose of TRI-611 in ALK-positive non-small cell lung cancer (NSCLC) patients on March 19, 2026. NCT07491497 is a Phase 1/2 trial enrolling 160 patients across nine U.S. sites, with the actual trial start date on March 11 and a primary completion goal set for May 2029. The key point is not just the trial initiation, but the fact that the target protein degrader platform has now advanced to human validation.
Drug Mechanism and Differentiation
TRI-611 is an oral, brain-penetrant ALK molecular glue degrader developed under a code name without a brand or international non-proprietary name. It binds to a distant degron site rather than the binding site of ALK tyrosine kinase inhibitors (TKIs), recruiting CRBN-based E3 ubiquitin ligase to degrade the EML4-ALK fusion protein. In preclinical studies, it degraded 30 EML4-ALK allelic variants, including wild-type and L1196M/G1202R compound mutations, and demonstrated tumor regression in patient-derived xenograft models following alectinib and lorlatinib treatment. However, current efficacy evidence is based on preclinical data, and ORR and PFS results in humans have not yet been reported.
Trial Design and Endpoints
The Phase 1 dose-escalation portion will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), safety, and pharmacokinetics, with two backfill cohorts. The Phase 2 portion will then divide patients into three cohorts (M1, M2, M3) based on prior ALK TKI treatment history to evaluate objective response rate (ORR) and anti-tumor activity. This design allows for the separate assessment of resistance mutation overcoming in previously treated patients and competitive positioning in the TKI-naïve group, though initial safety and exposure assurance in the dose-exploration phase remains a priority.
Market, Competition, and Regulatory Context
The global revenue of ALK-positive NSCLC therapies in 2024 was approximately $3 billion from Xalkori, Lorbrena, Alecensa, and Alunbrig combined. The standard competitive set includes Roche’s Alecensa (alectinib, ALK TKI), Pfizer’s Lorbrena (lorlatinib, ALK/ROS1 TKI), Takeda’s Alunbrig (brigatinib, ALK TKI), Xcovery’s Ensacove (ensartinib, ALK TKI), and Nuvalent (NUVL)’s next-generation ALK TKI, nelarotene, as a late-stage competitor. The FDA approved Lorbrena for first-line treatment on March 3, 2021, Alecensa as adjuvant therapy on April 18, 2024, and Ensacove for first-line treatment on December 18, 2024. TRI-611 is still in Phase 1/2 and lags behind these drugs in development, but if its mechanism of protein degradation via CRBN-mediated pathways, rather than binding site inhibition, proves effective in resistant patients, it could secure a distinct therapeutic position.
TRI-611 is the first Phase 1-stage molecular glue degrader targeting ALK fusion proteins to enter the approximately $3 billion ALK-positive NSCLC market. Short-term value hinges on whether the 160-patient Phase 1/2 trial can establish MTD, RP2D, and early response signals, including those in central nervous system metastases. In the medium to long term, it will need to compete with Alecensa, Lorbrena, Alunbrig, Ensacove, and late-stage nelarotene, but its CRBN-mediated degradation mechanism, which bypasses TKI binding site mutations, could serve as a differentiation basis in multi-drug resistant populations. For researchers and the industry, it represents the first clinical validation of a platform that directly degrades oncogenic fusion proteins via molecular glue. If patient data replicate the preclinical regression results, TRIANA’s follow-on targets and partnership potential will also rise.
Source: ClinicalTrials.gov (api_ct)